Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Guru Sonpavde"'
Publikováno v:
Expert Review of Anticancer Therapy. 22:1163-1175
Extensive experience outside the United States as well as randomized phase II and phase III data demonstrate thatThis review discusses the development and studies leading to the approval of
Autor:
Zachary Quinn, Benjamin Leiby, Guru Sonpavde, Atish D. Choudhury, Christopher Sweeney, David Einstein, Russell Szmulewitz, Oliver Sartor, Karen Knudsen, Eddy Shih-Hsin Yang, Wm. Kevin Kelly
Publikováno v:
Clin Cancer Res
Purpose: To identify the safety of niraparib, a PARP inhibitor, in combination with Radium-223 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) in men without known BRCA mutations. Patients and Methods: Men with progressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bae2ba1abe4544d7dac7706e355b456c
https://europepmc.org/articles/PMC9812873/
https://europepmc.org/articles/PMC9812873/
Autor:
Marco Bandini, Mohamed Ahmed, Giuseppe Basile, Nicholas Watkin, Viraj Master, Yao Zhu, Gagan Prakash, Alejandro Rodriguez, Mbaaga K. Ssebakumba, Riccardo Leni, Giuseppe Ottone Cirulli, Ben Ayres, Rachel Compitello, Filippo Pederzoli, Pankaj M. Joshi, Sanjay B. Kulkarni, Francesco Montorsi, Guru Sonpavde, Andrea Necchi, Philippe E. Spiess
Publikováno v:
Nature Reviews. Urology
Rare tumours such as penile carcinoma have been largely neglected by the urology scientific community in favour of more common — and, therefore, more easily fundable — diseases. Nevertheless, penile cancer represents a rising burden for health-ca
Autor:
Harish Seethapathy, Sarah Street, Xiao Wei, Shveta S. Motwani, Kerry L. Reynolds, Toni K. Choueiri, Nifasha Rusibamayila, Ian A. Strohbehn, Meghan Lee, M.D. Michaelson, Brad McGregor, Cristina Salabao, Guru Sonpavde, Meghan E. Sise, David E. Leaf, Shruti Gupta, Sophia H. Zhao, Donald F. Chute, Xin Gao, Marina D. Kaymakcalan, Osama E. Rahma
Publikováno v:
European Journal of Cancer. 157:50-58
Background In patients with genitourinary cancers, the effect of immune checkpoint inhibitors (ICIs) on kidney function is unknown. Patients and methods This is a retrospective cohort study of patients with renal cell carcinoma (RCC) and urothelial c
Autor:
Devika Das, Terry Hyslop, Steven R. Patierno, Guru Sonpavde, Bonnie LaCroix, Tian Zhang, Brendon M. Patierno, Julia Rasmussen, Andrew J. Armstrong, A. Oliver Sartor, Patrick Healy, Kouros Owzar, James D. Bearden, Jennifer A. Freedman, Michael Moses Goodman, Kellie Shobe, Matthew I. Milowsky, Mark D. Fleming, Megan Ann McNamara, Michael R. Harrison, Julie Kephart, William R. Berry, Rhonda Wilder, Monika Anand, Carol Winters, Rick A. Kittles, Rhonda L. Bitting, Dadong Zhang, Colleen Riggan, Daniel J. George, Alexander B. Sibley, Elisabeth I. Heath, Susan Halabi
Publikováno v:
Cancer
BACKGROUND: Retrospective analyses of randomized trials suggest that Black men with metastatic castration-resistant prostate cancer (mCRPC) have longer survival than White men. The authors conducted a prospective study of abiraterone acetate plus pre
Autor:
Song Gao, Shuaibin Wang, Zhiying Zhao, Chao Zhang, Zhicao Liu, Ping Ye, Zhifang Xu, Baozhu Yi, Kai Jiao, Gurudatta A. Naik, Shi Wei, Soroush Rais-Bahrami, Sejong Bae, Wei-Hsiung Yang, Guru Sonpavde, Runhua Liu, Lizhong Wang
Publikováno v:
Nature Communications. 13
Human tubulin beta class IVa (TUBB4A) is a member of the β-tubulin family. In most normal tissues, expression of TUBB4A is little to none, but it is highly expressed in human prostate cancer. Here we show that high expression levels of TUBB4A are as
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo
Autor:
Vadim S. Koshkin, Bernadett Szabados, Daniel Castellano, Matthew D. Galsky, Petros Grivas, Lucia Carril-Ajuria, Min Y. Teo, Daniele Raggi, Guru Sonpavde, Parissa Alerasool, Thomas Powles, Lillian Werner, Jacob Gaines, Xiao X. Wei, Ravindran Kanesvaran, Joaquim Bellmunt, Jonathan E. Rosenberg, Andrea Necchi, Noah M. Hahn, Rana R. McKay, Laura Morrison, Pedro Isaacsson Velho
Publikováno v:
J Urol
PURPOSE: Current first-line treatment options in patients with metastatic urothelial carcinoma (mUC) unfit to receive cisplatin-containing chemotherapy include PD-1/L1 inhibitors and carboplatin-containing chemotherapy. However, the optimal sequencin
Autor:
Amishi Yogesh Shah, Arlene O. Siefker-Radtke, Aradhana M. Venkatesan, Subrina Farah, Glenn J. Bubley, Mehmet Asim Bilen, Wanling Xie, Matthew T. Campbell, Guru Sonpavde, Kerry L. Kilbridge, Amir Mortazavi, Atish D. Choudhury, Toni K. Choueiri, Bradley Alexander McGregor, Andrew Schmidt, Rana R. McKay
Publikováno v:
Cancer. 127:840-849
Background In this multicenter, single-arm, multicohort, phase 2 trial, the efficacy of nivolumab and ipilimumab was evaluated in patients with advanced rare genitourinary cancers, including bladder and upper tract carcinoma of variant histology (BUT
Autor:
Arwa A. Alzaghal, Guru Sonpavde, Francesco Alessandrino, Atul B. Shinagare, Amin Nassar, Arvind Ravi, Rahul Gujrathi, Bradley Alexander McGregor
Publikováno v:
European Urology Oncology. 3:680-686
Reliable biomarkers to predict the response of metastatic urothelial cancer (mUC) to programmed death-1 and programmed death-ligand 1 (PD-1/PD-L1) inhibitors are being investigated. Texture analysis represents tumor heterogeneity and may serve as a p